Shandong Bailong Chuangyuan Bio-Tech Second Quarter 2024 Earnings: EPS: CN¥0.20 (vs CN¥0.15 in 2Q 2023)

Simply Wall St · 08/30 22:11

Shandong Bailong Chuangyuan Bio-Tech (SHSE:605016) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥279.2m (up 28% from 2Q 2023).
  • Net income: CN¥66.0m (up 42% from 2Q 2023).
  • Profit margin: 24% (up from 21% in 2Q 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥0.20 (up from CN¥0.15 in 2Q 2023).
earnings-and-revenue-growth
SHSE:605016 Earnings and Revenue Growth August 30th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shandong Bailong Chuangyuan Bio-Tech Earnings Insights

Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Food industry in China.

Performance of the Chinese Food industry.

The company's shares are up 14% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Shandong Bailong Chuangyuan Bio-Tech (including 1 which is a bit unpleasant).